![]() |
市场调查报告书
商品编码
1715191
欧洲液体活检采血管市场预测(2031年)-区域分析-按产品、材料、应用和最终用户Europe Blood Collection Tubes for Liquid Biopsy Market Forecast to 2031 - Regional Analysis - by Product, Material, Application, and End User |
2023年欧洲液体切片采集血管市场价值为309.49亿美元,预计到2031年将达到1217.4227亿美元;预计2023年至2031年的复合年增长率为18.7%。
液体活检相较于其他诊断检测技术的优势推动欧洲血液采集管用于液体活检市场
侵入性诊断程序会增加血肿、出血和组织损伤的风险,并在周围组织中播撒肿瘤细胞。因此,越来越多的患者倾向于采用非侵入性或微创性测试来进行诊断。研究人员可以透过血液样本的液体活检追踪实体肿瘤中的所有遗传和表观遗传学变化。由于液体活检是一种非侵入性诊断技术,因此患者的风险较小。此外,临床医生可以轻鬆地多次进行这些测试,因为这些过程不会对患者造成太多不适。由于使用先进的仪器,患者更喜欢微创手术,这使得临床医生或实验室人员能够以更少的疼痛、疤痕和风险进行更精细和复杂的工作。由于技术进步提高了可行性并缩短了处理时间,液体活检作为癌症患者组织活检的一种非侵入性替代方法,最近引起了人们的广泛关注。
电脑断层扫描 (CT)、磁振造影 (MRI) 和正子断层扫描 (PET) 等影像技术既昂贵又耗时。此外,它们还使患者接触外部放射线、静脉造影剂和放射性示踪剂等。影像学研究也无法提供关于肿瘤表型的任何信息,而肿瘤表型可能会随着治疗而改变。儘管组织活检技术可以提供有关肿瘤表型的信息,但考虑到成本限制和患者风险,进行连续组织活检是不可行的。相反,液体活检可以以相对较低的成本提供对癌症负担和表型资讯的几乎连续的评估。液体活检提供了评估各种生理或病理生理过程的非侵入性或微创性手段,从而取代组织活检或其他侵入性程序。在这种情况下,液体活检可以透过分析血液样本中的循环肿瘤细胞或循环游离核酸来避免内视镜检查、针吸活检或手术的需要。
欧洲液体切片采血管市场概况
根据2022年6月发表在《胸腔肿瘤学杂誌》的《德国肺癌》文章,癌症是德国第二大死因之一,占所有死亡人数的25%。男性和女性的年龄标准化发生率分别为 52.1% 和 32.7%(每 10 万人)。男性被诊断出罹患癌症的平均年龄为 70 岁,女性为 69 岁,且 52% 的患者处于 IV 期。因此,癌症发生率的不断上升推动了德国液体活检采血管市场的成长。此外,BARMER 还涵盖针对大肠直肠癌患者进行的 OncoBEAM RAS CRC IVD 测试。这种创新的液体活检诊断方法仅需使用单管血量即可对 RAS 突变进行全面评估。这种报销选择标誌着肿瘤治疗现代化的一个重要里程碑,使患者能够获得关键讯息,以便及时选择最合适的治疗方法。
欧洲液体切片采血管市场收入及预测(2031年)(百万美元)
欧洲液体切片采血管市场细分
欧洲液体切片采血管市场分为产品、材料、应用、最终用户、国家。
根据产品,欧洲液体切片采血管市场分为 ccfDNA/cfDNA 管、cfRNA 管、CTC 管、gDNA 管、细胞内 RNA 管等。 2023 年,ccfDNA/cfDNA 管部门占据欧洲液体活检采血管市场的最大份额。
从材质来看,欧洲液体切片采血管市场分为塑胶和玻璃。 2023 年,塑胶製品占据了欧洲液体活检采血管市场的较大份额。
根据应用,欧洲液体切片采血管市场分为体外诊断(IVD)和研究。 2023 年,体外诊断 (IVD) 领域占据了欧洲液体活检采血管市场的较大份额。
就最终用户而言,欧洲液体活检采血管市场分为基因诊断实验室、研发中心、传统诊断中心和其他。 2023 年,基因诊断实验室部门占据欧洲液体活检采血管市场的最大份额。
根据国家/地区,欧洲液体活检采血管市场分为英国、德国、法国、义大利、西班牙和欧洲其他地区。 2023 年,德国占据欧洲液体活检采血管市场的最大份额。
Biocept公司;精确科学公司; F.霍夫曼-罗氏有限公司; Greiner Bio-One International GmbH; MagBio Genomics 公司; Norgen Biotek 公司; QIAGEN NV;斯特雷克公司;和 Zymo Research Corporation 是欧洲液体活检采血管市场领先的公司之一。
The Europe blood collection tubes for liquid biopsy market was valued at US$ 30,949.00 million in 2023 and is expected to reach US$ 1,21,742.27 million by 2031; it is estimated to register a CAGR of 18.7% from 2023 to 2031.
Advantages of Liquid Biopsy Over Other Diagnostic Testing Techniques Drive Europe Blood Collection Tubes for Liquid Biopsy Market
Invasive diagnostic procedures increase the risk of hematoma, hemorrhage, and tissue damage, seeding tumor cells in surrounding tissues. As a result, there is a growing preference for noninvasive or minimally invasive tests among patients for diagnostic purposes. Researchers can trace all genetic and epigenetic changes in solid tumors through the liquid biopsy of blood samples. Patients are at lesser risk with liquid biopsies, since it is a noninvasive technique of diagnosis. Moreover, clinicians can readily conduct these tests multiple times, as the procedures don't subject patients to much discomfort. Patients prefer minimally invasive procedures due to the use of advanced instruments, which allow clinicians or laboratory personnel to perform more delicate and complex work with less pain, scarring, and risk. Liquid biopsy has recently gathered considerable interest as a noninvasive alternative to tissue biopsy in cancer patients, owing to technological advancements contributing to improved feasibility and reduced processing times.
Computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scan, among other imaging techniques, are expensive and time-consuming. Moreover, they expose patients to external radiation, intravenous contrast, and radioactive tracers, among others. Imaging studies also fail to provide any information about the phenotype of the tumor, which can change with the treatment given. Although tissue biopsy techniques can offer information on tumor phenotype information, it is not feasible to perform serial tissue biopsies, considering cost limitations and risks to patients. Liquid biopsy, on the contrary, could provide a virtually continuous assessment of cancer burden and phenotype information at a relatively low cost. Liquid biopsy offers noninvasive or minimally invasive means of assessing various physiological or pathophysiological processes, thereby replacing tissue biopsy or other invasive procedures. Liquid biopsy, in this case, could circumvent the need for endoscopy, needle biopsy, or surgery by analyzing a blood sample for circulating tumor cells or circulating free nucleic acids.
Europe Blood Collection Tubes for Liquid Biopsy Market Overview
According to the "Lung Cancer in Germany" article, published in the Journal of Thoracic Oncology in June 2022, cancer is among the second most frequent cause of death in Germany, accounting for 25% of all deaths. With an age-standardized incidence rate of 52.1% and 32.7% (per 100,000) in men and women, respectively. The average age at which individuals are diagnosed with cancer is 70 years in men and 69 years in women, and 52% of the total patients are at stage IV. The increasing prevalence of cancer thus fuels the growth of the blood collection tubes for liquid biopsy market in Germany. Moreover, BARMER covers the OncoBEAM RAS CRC IVD Test performed in colorectal cancer patients. This innovative liquid biopsy diagnostic method delivers a comprehensive evaluation of RAS mutations using blood volume as low as a single tube. This reimbursement option marks an important milestone in the modernization of oncology care, granting patients access to critical information for the timely selection of the most appropriate therapy.
Europe Blood Collection Tubes for Liquid Biopsy Market Revenue and Forecast to 2031 (US$ Million)
Europe Blood Collection Tubes for Liquid Biopsy Market Segmentation
The Europe blood collection tubes for liquid biopsy market is categorized into product, material, application, end user, country.
By product, the Europe blood collection tubes for liquid biopsy market is segmented into ccfDNA/cfDNA Tubes, cfRNA Tubes, CTC Tubes, gDNA Tubes, intracellular RNA Tubes, and others. The ccfDNA/cfDNA Tubes segment held the largest share of the Europe blood collection tubes for liquid biopsy market share in 2023.
In terms of material, the Europe blood collection tubes for liquid biopsy market is segmented into plastic and glass. The plastic segment held a larger share of the Europe blood collection tubes for liquid biopsy market share in 2023.
By application, the Europe blood collection tubes for liquid biopsy market is bifurcated into in-vitro diagnostics (IVD) and research. The in-vitro diagnostics (IVD) segment held a larger share of the Europe blood collection tubes for liquid biopsy market share in 2023.
In terms of end user, the Europe blood collection tubes for liquid biopsy market is segmented into genetic diagnostic labs, research and development centers, conventional diagnostic centers, and others. The genetic diagnostic labs segment held the largest share of the Europe blood collection tubes for liquid biopsy market share in 2023.
Based on country, the Europe blood collection tubes for liquid biopsy market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany segment held the largest share of Europe blood collection tubes for liquid biopsy market in 2023.
Biocept Inc; Exact Sciences Corp; F. Hoffmann-La Roche Ltd; Greiner Bio-One International GmbH; MagBio Genomics, Inc; Norgen Biotek Corp; QIAGEN NV; Streck Inc; and Zymo Research Corporation are some of the leading companies operating in the Europe blood collection tubes for liquid biopsy market.